Renew Biotechnologies
May 21, 2024
Renew BioTechnologies is dedicated to exploring and embracing groundbreaking biotechnologies and intellectual property. With a remarkable knack for capturing market share, Renew excels in leveraging its cutting-edge technologies and spearheads innovation in the field. Renowned for its strategic alliances and sponsored research agreements with leading universities, Renew consistently enjoys a robust pipeline of exciting new biotech projects, propelling the frontiers of scientific progress.
Recent News
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
- Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
- Growing collaboration with New York Kidney & Hypertension Medicine
- CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
